NASDAQ: AVDLAvadel Pharmaceuticals PLC Stock
$8.89+0.28 (+3.25%)
Updated Apr 30, 2025
AVDL Price
$8.89
Fair Value Price
-$0.43
Market Cap
$859.04M
52 Week Low
$6.38
52 Week High
$19.09
P/E
-17.43x
P/B
11.63x
P/S
5.91x
PEG
N/A
Dividend Yield
N/A
Revenue
$169.12M
Earnings
-$48.83M
Gross Margin
91%
Operating Margin
-22.62%
Profit Margin
-28.9%
Debt to Equity
1.22
Operating Cash Flow
-$47M
Beta
1.1
Next Earnings
May 6, 2025
Ex-Dividend
N/A
Next Dividend
N/A
AVDL Overview
Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is FT218, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine AVDL's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Pharmaceutical
Industry Rating
B
AVDL
Ranked#31 of 57
Ranked#31 of 57
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $7.66 | A | |
| $32.48 | A | |
| $26.90 | A |
Be the first to know about important AVDL news, forecast changes, insider trades & much more!
AVDL News
Overview
Due Diligence Score
–
Industry Average (27)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how AVDL scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
AVDL ($8.89) is overvalued by 2,184.74% relative to our estimate of its Fair Value price of -$0.43 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
AVDL ($8.89) is not significantly undervalued (2,184.74%) relative to our estimate of its Fair Value price of -$0.43 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
AVDL is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more AVDL due diligence checks available for Premium users.
Valuation
AVDL fair value
Fair Value of AVDL stock based on Discounted Cash Flow (DCF)
Price
$8.89
Fair Value
-$0.43
Undervalued by
2,184.74%
AVDL ($8.89) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
AVDL ($8.89) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
AVDL is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
AVDL price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-17.43x
Industry
21.23x
Market
29.18x
AVDL price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
11.63x
Industry
2.09x
AVDL is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
AVDL's financial health
Profit margin
Revenue
$50.4M
Net Income
-$5.0M
Profit Margin
-10%
AVDL's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
AVDL's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$164.2M
Liabilities
$90.4M
Debt to equity
1.22
AVDL's short-term assets ($134.21M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
AVDL's short-term assets ($134.21M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
AVDL's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
AVDL's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$7.9M
Investing
$14.9M
Financing
$880.0k
AVDL's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
AVDL vs Pharmaceutical Stocks
Avadel Pharmaceuticals Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.